DTaP-poliovirus vaccine - Pfizer

Drug Profile

DTaP-poliovirus vaccine - Pfizer

Alternative Names: Certiva-IPV; DI-TE-KI-POL; DTaP-IPV; DTaP-IPV vaccine; North American Vaccine (NAV) combination vaccine (DTaP + IPV)

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Nonindustrial source; North American Vaccine; Statens Serum Institut
  • Developer North American Vaccine; Statens Serum Institut
  • Class Bacterial vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Diphtheria; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 16 Jan 2017 Statens Serum Institut sold its vaccine production business to AJ Vaccines
  • 27 Jun 2000 North American Vaccine has been acquired by and merged into Baxter International
  • 16 May 2000 A clinical study has been added to the adverse events section and the Bacterial and Viral Infections immunogenicity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top